Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225-FL-020

A radioconjugate composed of FL-020, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FL-020, FL-020 targets and binds to PSMA-expressing tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[225Ac]-FL-020
[225Ac]Ac-FL-020
actinium Ac 225 FL-020
actinium Ac 225-labeled FL-020
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search